Huiqiang Zhao

Prof. Dr. Huiqiang Zhao

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
RLRuifeng Liu
Ruifeng Liu
XGXiangyu Gao
Xiangyu Gao
SLSiwen Liang
Siwen Liang
HZHuiqiang Zhao
Huiqiang Zhao
Background: Most of coronary artery ectasia (CAE) patients have comorbid coronary atherosclerosis. It was lack of prognostic data for CAE patients with coronary heart disease (CHD) and for whom with acute myocardial infarction (AMI).Objective: To determine the overall prognosis for CAE patients.Materials and methods: This study was a retrospective cohort study. Fifty-one patients with CAE and comorbid AMI (CAE + AMI) and 108 patients with CAE and comorbid CHD (CAE + CHD) were enrolled and matched to non-CAE subjects at a ratio of 1:3 using a propensity score method, respectively. Controls for CAE + AMI group were 153 AMI patients, controls for CAE group were 324 CHD patients and 329 participants with relatively normal coronary arteries (CON). We followed them up to observe major cardiovascular events (MACE).Results: The Kaplan-Meier curves showed that the prognosis in CAE + AMI group was worse than in AMI group (5-year non-MACE rate: 62.70% vs. 79.70%, P = 0.010), the prognosis in CAE group was worse than in CHD and CON groups (5-year non-MACE rate: 74.10% vs. 85.80% and 96.70%, respectively, P = 0.000). The main MACEs in CAE + AMI and CAE groups were AMI reoccurrence (19.61% vs. 4.57%, P = 0.002) and re-hospitalization due to repeated angina pectoris (14.81% vs. 8.33% and 2.74%, P = 0.000), respectively. Additionally, the COX regression analysis revealed that the protective factors for preventing MACE in CAE + AMI group included antiplatelet agents (hazard ratio = 0.234, P = 0.016) and angiotensin-converting enzyme inhibitor/angiotensin receptor inhibitor (ACEI/ARB, hazard ratio = 0.317, P = 0.037). Whereas the main factor promoting MACE in CAE group was the degree of coronary stenosis (Gensini score, hazard ratio = 1.011, P = 0.022).Conclusion: The prognosis of patients with CAE + AMI was worse than that of those with AMI. The overall prognosis of patients with CAE was worse than that of those with CHD. CAE + AMI and CAE groups had different characteristics; the former was prone to AMI reoccurrence, and the latter was prone to repeated angina pectoris. To prevent MACE, medications, including antiplatelets and ACEI/ARBs, are indicated for patients with CAE + AMI, whereas prevention of the progression of atherosclerotic lesions is indicated for patients with CAE.

28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
RLRUI feng Liu
RUI feng Liu
QSQianqian Sheng
Qianqian Sheng
SLSiwen Liang
Siwen Liang
HZHuiqiang Zhao
Huiqiang Zhao
Background/aim: Damage to elastin fibres in coronary media might lead to coronary artery ectasia (CAE). This study evaluated whether CAE can be distinguished by detecting circulating soluble elastin (s-elastin), which is a degradation product of elastin fibres, and elastase, which is the main enzyme of elastin fibres. Materials and methods: Fifty-eight patients with CAE, 58 with coronary heart disease (CHD) and 61 with relatively normal coronary arteries, were included. Circulating s-elastin and elastase were measured, and receiver operating characteristic curves were used to demonstrate their respective optimal cut-off values for predicting CAE. Results: The concentrations of s-elastin and elastase were higher in the CAE group than in the CHD and relatively-normal-coronary groups. Their cut-off values for screening of CAE were 13.148 ng/mL and 25.549 ng/mL, respectively; for sensitivity of CAE were 0.690 and 0.773, respectively; and for specificity of CAE were 0.862 and 0.571, respectively. A combination of s-elastin and elastase in series (one of the two higher than its cut-off value) had a better sensitivity for screening for CAE, whereas their combination in parallel (both higher than their cut-off values) had a better specificity. Conclusion: Circulating s-elastin and elastase are promising biomarkers for assisting in CAE diagnosis.

26 April 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
RLRui-Feng Liu
Rui-Feng Liu
XGXiang-Yu Gao
Xiang-Yu Gao
SLSi-Wen Liang
Si-Wen Liang
HZHuiqiang Zhao
Huiqiang Zhao
There is no consensus on the antithrombotic treatment strategy for patients with coronary artery ectasia (CAE). This case reports the dynamic observation of a patient for 48 mo after a diagnosis of CAE with acute myocardial infarction (AMI). The first antithrombotic agents used were aspirin (100 mg/d) and clopidogrel (75 mg/d). During the sixth month of observation, a second AMI occurred involving the same culprit vessel; therefore, antithrombotic agents were changed to aspirin (100 mg/d) and ticagrelor (90 mg twice per day). Twelve months after the second AMI, an attempt to reduce the dosage ticagrelor failed; therefore the original dose was continued. The CAE was relatively stable during the following 4 years. This case indicates that a combination of aspirin and ticagrelor may be more effective for CAE patients with AMI than aspirin and clopidogrel.

22 July 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
RLRUI feng Liu
RUI feng Liu
XGXiangyu Gao
Xiangyu Gao
JFJihong Fan
Jihong Fan
HZHuiqiang Zhao
Huiqiang Zhao
Background: Ventricular fibrillation (VF) is a life-threatening complication of acute myocardial infarction (AMI), particularly in patients undergoing percutaneous coronary intervention (PCI). Early identification of high-risk patients is crucial for implementing preventive measures and improving outcomes. Methods: This retrospective study analyzed clinical, laboratory, and angiographic data from 155 AMI patients to identify predictors of VF during PCI. Variable selection was performed using least absolute shrinkage and selection operator (LASSO) regression, elastic net regression, and random forest. Independent predictors were identified through multivariable logistic regression, and a nomogram was developed and validated to predict VF risk. Model performance was assessed using receiver operating characteristic (ROC) and calibration curves. Results: Independent predictors of VF included diabetes (OR = 3.676 (1.365–10.668); p = 0.012), neutrophil-to-lymphocyte ratio (NLR) (odds ratio (OR) = 1.149 (1.053–1.265); p = 0.002), right coronary artery (RCA) intervention (OR = 3.185 (1.088–9.804); p = 0.037), Gensini score (OR = 1.020 (1.007–1.033); p = 0.003), and absence of beta blockers (OR = 0.168 (0.054–0.472); p = 0.001). The nomogram, incorporating these predictors, demonstrated a strong discriminative ability with an area under the ROC curve (AUC) of 0.882 (0.825–0.939) and good calibration (Hosmer–Lemeshow test, p = 0.769). The calibration curve showed a strong alignment between predicted probabilities and observed outcomes, with a mean absolute error of 0.033. Conclusions: This study identified diabetes, NLR, RCA intervention, Gensini score, and absence of beta-blocker use as key predictors of VF during PCI in AMI patients. A nomogram incorporating these factors showed strong predictive performance, aiding clinicians in identifying high-risk patients for targeted preventive strategies.